請用此 Handle URI 來引用此文件:
http://tdr.lib.ntu.edu.tw/jspui/handle/123456789/28271
完整後設資料紀錄
DC 欄位 | 值 | 語言 |
---|---|---|
dc.contributor.advisor | 陳青周(Ching-Chow Chen) | |
dc.contributor.author | Wen-Yu Huang | en |
dc.contributor.author | 黃文郁 | zh_TW |
dc.date.accessioned | 2021-06-13T00:04:03Z | - |
dc.date.available | 2012-08-08 | |
dc.date.copyright | 2007-08-08 | |
dc.date.issued | 2007 | |
dc.date.submitted | 2007-07-29 | |
dc.identifier.citation | Alarcon-Vargas, D. and Ronai, Z. 2002. p53-Mdm2--the affair that never ends. Carcinogenesis 23(4): 541-547.
Almasan, A., Yin, Y., Kelly, R.E., Lee, E.Y., Bradley, A., Li, W., Bertino, J.R., and Wahl, G.M. 1995. Deficiency of retinoblastoma protein leads to inappropriate S-phase entry, activation of E2F-responsive genes, and apoptosis. Proc Natl Acad Sci U S A 92(12): 5436-5440. Appella, E. and Anderson, C.W. 2001. Post-translational modifications and activation of p53 by genotoxic stresses. Eur J Biochem 268(10): 2764-2772. Appleman, J.R., Prendergast, N., Delcamp, T.J., Freisheim, J.H., and Blakley, R.L. 1988. Kinetics of the formation and isomerization of methotrexate complexes of recombinant human dihydrofolate reductase. J Biol Chem 263(21): 10304-10313. Assaraf, Y.G. 2007. Molecular basis of antifolate resistance. Cancer Metastasis Rev 26(1): 153-181. Beardsley, G.P., Moroson, B.A., Taylor, E.C., and Moran, R.G. 1989. A new folate antimetabolite, 5,10-dideaza-5,6,7,8-tetrahydrofolate is a potent inhibitor of de novo purine synthesis. J Biol Chem 264(1): 328-333. Bischof, O., Schwamborn, K., Martin, N., Werner, A., Sustmann, C., Grosschedl, R., and Dejean, A. 2006. The E3 SUMO ligase PIASy is a regulator of cellular senescence and apoptosis. Mol Cell 22(6): 783-794. Bode, A.M. and Dong, Z. 2004. Post-translational modification of p53 in tumorigenesis. Nat Rev Cancer 4(10): 793-805. Brengauz-Breitmann, M., Friedman, E., Savion, S., Torchinsky, A., Fein, A., and Toder, V. 2006. Involvement of NF-kappaB in the response of embryonic cells to methotrexate. Reprod Toxicol 22(3): 469-478. Brooks, C.L. and Gu, W. 2006. p53 ubiquitination: Mdm2 and beyond. Mol Cell 21(3): 307-315. Bulavin, D.V., Saito, S., Hollander, M.C., Sakaguchi, K., Anderson, C.W., Appella, E., and Fornace, A.J., Jr. 1999. Phosphorylation of human p53 by p38 kinase coordinates N-terminal phosphorylation and apoptosis in response to UV radiation. Embo J 18(23): 6845-6854. Cam, H. and Dynlacht, B.D. 2003. Emerging roles for E2F: beyond the G1/S transition and DNA replication. Cancer Cell 3(4): 311-316. Canman, C.E., Gilmer, T.M., Coutts, S.B., and Kastan, M.B. 1995. Growth factor modulation of p53-mediated growth arrest versus apoptosis. Genes Dev 9(5): 600-611. Chan, W.M., Mak, M.C., Fung, T.K., Lau, A., Siu, W.Y., and Poon, R.Y. 2006. Ubiquitination of p53 at multiple sites in the DNA-binding domain. Mol Cancer Res 4(1): 15-25. Cocconi, G., Cunningham, D., Van Cutsem, E., Francois, E., Gustavsson, B., van Hazel, G., Kerr, D., Possinger, K., and Hietschold, S.M. 1998. Open, randomized, multicenter trial of raltitrexed versus fluorouracil plus high-dose leucovorin in patients with advanced colorectal cancer. Tomudex Colorectal Cancer Study Group. J Clin Oncol 16(9): 2943-2952. Craig, A.L., Burch, L., Vojtesek, B., Mikutowska, J., Thompson, A., and Hupp, T.R. 1999. Novel phosphorylation sites of human tumour suppressor protein p53 at Ser20 and Thr18 that disrupt the binding of mdm2 (mouse double minute 2) protein are modified in human cancers. Biochem J 342 ( Pt 1): 133-141. Cummins, J.M., Rago, C., Kohli, M., Kinzler, K.W., Lengauer, C., and Vogelstein, B. 2004. Tumour suppression: disruption of HAUSP gene stabilizes p53. Nature 428(6982): 1 p following 486. Das, K.C. and White, C.W. 1997. Activation of NF-kappaB by antineoplastic agents. Role of protein kinase C. J Biol Chem 272(23): 14914-14920. de Graaf, P., Little, N.A., Ramos, Y.F., Meulmeester, E., Letteboer, S.J., and Jochemsen, A.G. 2003. Hdmx protein stability is regulated by the ubiquitin ligase activity of Mdm2. J Biol Chem 278(40): 38315-38324. Dohmen, R.J. 2004. SUMO protein modification. Biochim Biophys Acta 1695(1-3): 113-131. Domin, B.A., Cheng, Y.C., and Hakala, M.T. 1982. Properties of dihydrofolate reductase from a methotrexate-resistant subline of human KB cells and comparison with enzyme from KB parent cells and mouse S180 AT/3000 cells. Mol Pharmacol 21(1): 231-238. Fahy, B.N., Schlieman, M.G., Virudachalam, S., and Bold, R.J. 2004. Inhibition of AKT abrogates chemotherapy-induced NF-kappaB survival mechanisms: implications for therapy in pancreatic cancer. J Am Coll Surg 198(4): 591-599. Feng, L., Lin, T., Uranishi, H., Gu, W., and Xu, Y. 2005. Functional analysis of the roles of posttranslational modifications at the p53 C terminus in regulating p53 stability and activity. Mol Cell Biol 25(13): 5389-5395. Francoz, S., Froment, P., Bogaerts, S., De Clercq, S., Maetens, M., Doumont, G., Bellefroid, E., and Marine, J.C. 2006. Mdm4 and Mdm2 cooperate to inhibit p53 activity in proliferating and quiescent cells in vivo. Proc Natl Acad Sci U S A 103(9): 3232-3237. Gatti, A., Li, H.H., Traugh, J.A., and Liu, X. 2000. Phosphorylation of human p53 on Thr-55. Biochemistry 39(32): 9837-9842. Giacinti, C. and Giordano, A. 2006. RB and cell cycle progression. Oncogene 25(38): 5220-5227. Goker, E., Waltham, M., Kheradpour, A., Trippett, T., Mazumdar, M., Elisseyeff, Y., Schnieders, B., Steinherz, P., Tan, C., Berman, E., and et al. 1995. Amplification of the dihydrofolate reductase gene is a mechanism of acquired resistance to methotrexate in patients with acute lymphoblastic leukemia and is correlated with p53 gene mutations. Blood 86(2): 677-684. Gostissa, M., Hengstermann, A., Fogal, V., Sandy, P., Schwarz, S.E., Scheffner, M., and Del Sal, G. 1999. Activation of p53 by conjugation to the ubiquitin-like protein SUMO-1. Embo J 18(22): 6462-6471. Goulian, M., Bleile, B., and Tseng, B.Y. 1980. Methotrexate-induced misincorporation of uracil into DNA. Proc Natl Acad Sci U S A 77(4): 1956-1960. Gudas, J.M., Nguyen, H., Li, T., Sadzewicz, L., Robey, R., Wosikowski, K., and Cowan, K.H. 1996. Drug-resistant breast cancer cells frequently retain expression of a functional wild-type p53 protein. Carcinogenesis 17(7): 1417-1427. Hanna, N., Shepherd, F.A., Fossella, F.V., Pereira, J.R., De Marinis, F., von Pawel, J., Gatzemeier, U., Tsao, T.C., Pless, M., Muller, T., Lim, H.L., Desch, C., Szondy, K., Gervais, R., Shaharyar, Manegold, C., Paul, S., Paoletti, P., Einhorn, L., and Bunn, P.A., Jr. 2004. Randomized phase III trial of pemetrexed versus docetaxel in patients with non-small-cell lung cancer previously treated with chemotherapy. J Clin Oncol 22(9): 1589-1597. Harper, J.W. 2004. Neddylating the guardian; Mdm2 catalyzed conjugation of Nedd8 to p53. Cell 118(1): 2-4. Harris, S.L. and Levine, A.J. 2005. The p53 pathway: positive and negative feedback loops. Oncogene 24(17): 2899-2908. Hawkins, D.S., Demers, G.W., and Galloway, D.A. 1996. Inactivation of p53 enhances sensitivity to multiple chemotherapeutic agents. Cancer Res 56(4): 892-898. Hay, R.T. 2005. SUMO: a history of modification. Mol Cell 18(1): 1-12. He, J., Zhou, F., Shao, K., Hang, J., Wang, H., Rayburn, E., Xiao, Z.X., Lee, S.W., Xue, Q., Feng, X.L., Shi, S.S., Zhang, C.Y., and Zhang, S. 2007. Overexpression of Pin1 in non-small cell lung cancer (NSCLC) and its correlation with lymph node metastases. Lung Cancer 56(1): 51-58. Heenen, M., Laporte, M., Noel, J.C., and de Graef, C. 1998. Methotrexate induces apoptotic cell death in human keratinocytes. Arch Dermatol Res 290(5): 240-245. Horn, H.F. and Vousden, K.H. 2007. Coping with stress: multiple ways to activate p53. Oncogene 26(9): 1306-1316. Houtgraaf, J.H., Versmissen, J., and van der Giessen, W.J. 2006. A concise review of DNA damage checkpoints and repair in mammalian cells. Cardiovasc Revasc Med 7(3): 165-172. Hu, M., Li, P., Li, M., Li, W., Yao, T., Wu, J.W., Gu, W., Cohen, R.E., and Shi, Y. 2002. Crystal structure of a UBP-family deubiquitinating enzyme in isolation and in complex with ubiquitin aldehyde. Cell 111(7): 1041-1054. Huang, C., Ma, W.Y., Maxiner, A., Sun, Y., and Dong, Z. 1999a. p38 kinase mediates UV-induced phosphorylation of p53 protein at serine 389. J Biol Chem 274(18): 12229-12235. Huang, R.F., Ho, Y.H., Lin, H.L., Wei, J.S., and Liu, T.Z. 1999b. Folate deficiency induces a cell cycle-specific apoptosis in HepG2 cells. J Nutr 129(1): 25-31. Huang, W.C., Ju, T.K., Hung, M.C., and Chen, C.C. 2007. Phosphorylation of CBP by IKKalpha promotes cell growth by switching the binding preference of CBP from p53 to NF-kappaB. Mol Cell 26(1): 75-87. Iida, K., Nobori, T., Matsumine, A., Isaka, A., Seto, M., Shiraishi, T., and Uchida, A. 2003. Effect of retinoblastoma tumor suppressor gene expression on chemosensitivity of human osteosarcoma cell lines. Oncol Rep 10(6): 1961-1965. Ito, A., Kawaguchi, Y., Lai, C.H., Kovacs, J.J., Higashimoto, Y., Appella, E., and Yao, T.P. 2002. MDM2-HDAC1-mediated deacetylation of p53 is required for its degradation. Embo J 21(22): 6236-6245. Juan, L.J., Shia, W.J., Chen, M.H., Yang, W.M., Seto, E., Lin, Y.S., and Wu, C.W. 2000. Histone deacetylases specifically down-regulate p53-dependent gene activation. J Biol Chem 275(27): 20436-20443. Kawai, H., Wiederschain, D., Kitao, H., Stuart, J., Tsai, K.K., and Yuan, Z.M. 2003. DNA damage-induced MDMX degradation is mediated by MDM2. J Biol Chem 278(46): 45946-45953. Khosravi, R., Maya, R., Gottlieb, T., Oren, M., Shiloh, Y., and Shkedy, D. 1999. Rapid ATM-dependent phosphorylation of MDM2 precedes p53 accumulation in response to DNA damage. Proc Natl Acad Sci U S A 96(26): 14973-14977. Kim, Y.K., Lee, E.K., Kang, J.K., Kim, J.A., You, J.S., Park, J.H., Seo, D.W., Hwang, J.W., Kim, S.N., Lee, H.Y., Lee, H.W., and Han, J.W. 2006. Activation of NF-kappaB by HDAC inhibitor apicidin through Sp1-dependent de novo protein synthesis: its implication for resistance to apoptosis. Cell Death Differ 13(12): 2033-2041. Konikova, E. and Kusenda, J. 2003. Altered expression of p53 and MDM2 proteins in hematological malignancies. Neoplasma 50(1): 31-40. Lane, D.P. and Crawford, L.V. 1979. T antigen is bound to a host protein in SV40-transformed cells. Nature 278(5701): 261-263. Lavin, M.F. and Gueven, N. 2006. The complexity of p53 stabilization and activation. Cell Death Differ 13(6): 941-950. Lavrik, I., Golks, A., and Krammer, P.H. 2005. Death receptor signaling. J Cell Sci 118(Pt 2): 265-267. Li, J.C. and Kaminskas, E. 1984. Accumulation of DNA strand breaks and methotrexate cytotoxicity. Proc Natl Acad Sci U S A 81(18): 5694-5698. Li, M., Brooks, C.L., Kon, N., and Gu, W. 2004. A dynamic role of HAUSP in the p53-Mdm2 pathway. Mol Cell 13(6): 879-886. Li, M., Brooks, C.L., Wu-Baer, F., Chen, D., Baer, R., and Gu, W. 2003. Mono- versus polyubiquitination: differential control of p53 fate by Mdm2. Science 302(5652): 1972-1975. Li, M., Chen, D., Shiloh, A., Luo, J., Nikolaev, A.Y., Qin, J., and Gu, W. 2002a. Deubiquitination of p53 by HAUSP is an important pathway for p53 stabilization. Nature 416(6881): 648-653. Li, M., Luo, J., Brooks, C.L., and Gu, W. 2002b. Acetylation of p53 inhibits its ubiquitination by Mdm2. J Biol Chem 277(52): 50607-50611. Li, T., Santockyte, R., Shen, R.F., Tekle, E., Wang, G., Yang, D.C., and Chock, P.B. 2006. Expression of SUMO-2/3 induced senescence through p53- and pRB-mediated pathways. J Biol Chem 281(47): 36221-36227. Lim, K.P., Sharifah, H., Lau, S.H., Teo, S.H., and Cheong, S.C. 2005. Alterations of the p14ARF-p53-MDM2 pathway in oral squamous cell carcinoma: MDM2 overexpression is a common event. Oncol Rep 14(4): 963-968. Linzer, D.I., Maltzman, W., and Levine, A.J. 1979. The SV40 A gene product is required for the production of a 54,000 MW cellular tumor antigen. Virology 98(2): 308-318. Liu, S., Bishop, W.R., and Liu, M. 2003. Differential effects of cell cycle regulatory protein p21(WAF1/Cip1) on apoptosis and sensitivity to cancer chemotherapy. Drug Resist Updat 6(4): 183-195. Liu, Y., Denlinger, C.E., Rundall, B.K., Smith, P.W., and Jones, D.R. 2006. Suberoylanilide hydroxamic acid induces Akt-mediated phosphorylation of p300, which promotes acetylation and transcriptional activation of RelA/p65. J Biol Chem 281(42): 31359-31368. Lowe, S.W., Ruley, H.E., Jacks, T., and Housman, D.E. 1993. p53-dependent apoptosis modulates the cytotoxicity of anticancer agents. Cell 74(6): 957-967. Mantesso, A., Loducca, S.V., Bendit, I., Garicochea, B., Nunes, F.D., and de Araujo, V.C. 2004. Mdm2 mRNA expression in salivary gland tumour cell lines. J Oral Pathol Med 33(2): 96-101. Maya, R., Balass, M., Kim, S.T., Shkedy, D., Leal, J.F., Shifman, O., Moas, M., Buschmann, T., Ronai, Z., Shiloh, Y., Kastan, M.B., Katzir, E., and Oren, M. 2001. ATM-dependent phosphorylation of Mdm2 on serine 395: role in p53 activation by DNA damage. Genes Dev 15(9): 1067-1077. Muller, S., Berger, M., Lehembre, F., Seeler, J.S., Haupt, Y., and Dejean, A. 2000. c-Jun and p53 activity is modulated by SUMO-1 modification. J Biol Chem 275(18): 13321-13329. Nakanishi, C. and Toi, M. 2005. Nuclear factor-kappaB inhibitors as sensitizers to anticancer drugs. Nat Rev Cancer 5(4): 297-309. Okamoto, K., Li, H., Jensen, M.R., Zhang, T., Taya, Y., Thorgeirsson, S.S., and Prives, C. 2002. Cyclin G recruits PP2A to dephosphorylate Mdm2. Mol Cell 9(4): 761-771. Olivier, M., Hussain, S.P., Caron de Fromentel, C., Hainaut, P., and Harris, C.C. 2004. TP53 mutation spectra and load: a tool for generating hypotheses on the etiology of cancer. IARC Sci Publ(157): 247-270. Pan, Y. and Chen, J. 2003. MDM2 promotes ubiquitination and degradation of MDMX. Mol Cell Biol 23(15): 5113-5121. Pan, Z.Q., Kentsis, A., Dias, D.C., Yamoah, K., and Wu, K. 2004. Nedd8 on cullin: building an expressway to protein destruction. Oncogene 23(11): 1985-1997. Papaconstantinou, H.T., Xie, C., Zhang, W., Ansari, N.H., Hellmich, M.R., Townsend, C.M., Jr., and Ko, T.C. 2001. The role of caspases in methotrexate-induced gastrointestinal toxicity. Surgery 130(5): 859-865. Phelps, M., Darley, M., Primrose, J.N., and Blaydes, J.P. 2003. p53-independent activation of the hdm2-P2 promoter through multiple transcription factor response elements results in elevated hdm2 expression in estrogen receptor alpha-positive breast cancer cells. Cancer Res 63(10): 2616-2623. Pickart, C.M. 2001. Mechanisms underlying ubiquitination. Annu Rev Biochem 70: 503-533. Prives, C. and Hall, P.A. 1999. The p53 pathway. J Pathol 187(1): 112-126. Rodriguez, M.S., Desterro, J.M., Lain, S., Midgley, C.A., Lane, D.P., and Hay, R.T. 1999. SUMO-1 modification activates the transcriptional response of p53. Embo J 18(22): 6455-6461. Rosowsky, A., Wright, J.E., Vaidya, C.M., and Forsch, R.A. 2000. The effect of side-chain, para-aminobenzoyl region, and B-ring modifications on dihydrofolate reductase binding, influx via the reduced folate carrier, and cytotoxicity of the potent nonpolyglutamatable antifolate N(alpha)-(4-amino-4-deoxypteroyl)-N(delta)-hemiphthaloyl-L- ornithine. Pharmacol Ther 85(3): 191-205. Saito, S., Goodarzi, A.A., Higashimoto, Y., Noda, Y., Lees-Miller, S.P., Appella, E., and Anderson, C.W. 2002. ATM mediates phosphorylation at multiple p53 sites, including Ser(46), in response to ionizing radiation. J Biol Chem 277(15): 12491-12494. Saitoh, H. and Hinchey, J. 2000. Functional heterogeneity of small ubiquitin-related protein modifiers SUMO-1 versus SUMO-2/3. J Biol Chem 275(9): 6252-6258. Sakaguchi, K., Saito, S., Higashimoto, Y., Roy, S., Anderson, C.W., and Appella, E. 2000. Damage-mediated phosphorylation of human p53 threonine 18 through a cascade mediated by a casein 1-like kinase. Effect on Mdm2 binding. J Biol Chem 275(13): 9278-9283. Schornagel, J.H., Verweij, J., de Mulder, P.H., Cognetti, F., Vermorken, J.B., Cappelaere, P., Armand, J.P., Wildiers, J., de Graeff, A., Clavel, M., and et al. 1995. Randomized phase III trial of edatrexate versus methotrexate in patients with metastatic and/or recurrent squamous cell carcinoma of the head and neck: a European Organization for Research and Treatment of Cancer Head and Neck Cancer Cooperative Group study. J Clin Oncol 13(7): 1649-1655. Sharp, D.A., Kratowicz, S.A., Sank, M.J., and George, D.L. 1999. Stabilization of the MDM2 oncoprotein by interaction with the structurally related MDMX protein. J Biol Chem 274(53): 38189-38196. She, Q.B., Chen, N., and Dong, Z. 2000. ERKs and p38 kinase phosphorylate p53 protein at serine 15 in response to UV radiation. J Biol Chem 275(27): 20444-20449. Shvarts, A., Steegenga, W.T., Riteco, N., van Laar, T., Dekker, P., Bazuine, M., van Ham, R.C., van der Houven van Oordt, W., Hateboer, G., van der Eb, A.J., and Jochemsen, A.G. 1996. MDMX: a novel p53-binding protein with some functional properties of MDM2. Embo J 15(19): 5349-5357. Sirotnak, F.M., DeGraw, J.I., Moccio, D.M., Samuels, L.L., and Goutas, L.J. 1984. New folate analogs of the 10-deaza-aminopterin series. Basis for structural design and biochemical and pharmacologic properties. Cancer Chemother Pharmacol 12(1): 18-25. Smith, M.L. and Fornace, A.J., Jr. 1996. The two faces of tumor suppressor p53. Am J Pathol 148(4): 1019-1022. Susin, S.A., Zamzami, N., and Kroemer, G. 1998. Mitochondria as regulators of apoptosis: doubt no more. Biochim Biophys Acta 1366(1-2): 151-165. Sykes, S.M., Mellert, H.S., Holbert, M.A., Li, K., Marmorstein, R., Lane, W.S., and McMahon, S.B. 2006. Acetylation of the p53 DNA-binding domain regulates apoptosis induction. Mol Cell 24(6): 841-851. Tang, Y., Luo, J., Zhang, W., and Gu, W. 2006. Tip60-dependent acetylation of p53 modulates the decision between cell-cycle arrest and apoptosis. Mol Cell 24(6): 827-839. Tanimura, S., Ohtsuka, S., Mitsui, K., Shirouzu, K., Yoshimura, A., and Ohtsubo, M. 1999. MDM2 interacts with MDMX through their RING finger domains. FEBS Lett 447(1): 5-9. Tibbetts, R.S., Brumbaugh, K.M., Williams, J.M., Sarkaria, J.N., Cliby, W.A., Shieh, S.Y., Taya, Y., Prives, C., and Abraham, R.T. 1999. A role for ATR in the DNA damage-induced phosphorylation of p53. Genes Dev 13(2): 152-157. Toledo, F. and Wahl, G.M. 2006. Regulating the p53 pathway: in vitro hypotheses, in vivo veritas. Nat Rev Cancer 6(12): 909-923. Uldrijan, S., Pannekoek, W.J., and Vousden, K.H. 2007. An essential function of the extreme C-terminus of MDM2 can be provided by MDMX. Embo J 26(1): 102-112. Walker, P.R., Smith, B., Carson, C., LeBlanc, J., Sikorska, M., Woodhouse, C.S., and Morgan, A.C. 1997. Induction of apoptosis in neoplastic cells by depletion of vitamin B12. Cell Death Differ 4(3): 233-241. Wang, X., Taplick, J., Geva, N., and Oren, M. 2004. Inhibition of p53 degradation by Mdm2 acetylation. FEBS Lett 561(1-3): 195-201. Waterman, M.J., Stavridi, E.S., Waterman, J.L., and Halazonetis, T.D. 1998. ATM-dependent activation of p53 involves dephosphorylation and association with 14-3-3 proteins. Nat Genet 19(2): 175-178. Watson, I.R. and Irwin, M.S. 2006. Ubiquitin and ubiquitin-like modifications of the p53 family. Neoplasia 8(8): 655-666. Webster, G.A. and Perkins, N.D. 1999. Transcriptional cross talk between NF-kappaB and p53. Mol Cell Biol 19(5): 3485-3495. Xirodimas, D.P., Saville, M.K., Bourdon, J.C., Hay, R.T., and Lane, D.P. 2004. Mdm2-mediated NEDD8 conjugation of p53 inhibits its transcriptional activity. Cell 118(1): 83-97. Yeh, E.T., Gong, L., and Kamitani, T. 2000. Ubiquitin-like proteins: new wines in new bottles. Gene 248(1-2): 1-14. Zauberman, A., Barak, Y., Ragimov, N., Levy, N., and Oren, M. 1993. Sequence-specific DNA binding by p53: identification of target sites and lack of binding to p53 - MDM2 complexes. Embo J 12(7): 2799-2808. Zhao, Y., Lu, S., Wu, L., Chai, G., Wang, H., Chen, Y., Sun, J., Yu, Y., Zhou, W., Zheng, Q., Wu, M., Otterson, G.A., and Zhu, W.G. 2006. Acetylation of p53 at lysine 373/382 by the histone deacetylase inhibitor depsipeptide induces expression of p21(Waf1/Cip1). Mol Cell Biol 26(7): 2782-2790. | |
dc.identifier.uri | http://tdr.lib.ntu.edu.tw/jspui/handle/123456789/28271 | - |
dc.description.abstract | Methotrexate (MTX) 為dihydrofolate reductase (DHFR) 抑制劑,可抑制癌細胞之葉酸循環,干擾DNA合成所需之one carbon donor而中止細胞週期,促使細胞之凋亡。HDAC (histone deacetyltranferase) 可移去染色體組織蛋白 (histone) 之乙醯基,使DNA與組織蛋白緊密纏繞而抑制基因之表現,目前發現許多癌症皆會表現HDACs,降低抑癌基因(例如p53、p21、Rb等)之表現,因此HDACs抑制劑為發展抗癌藥物的新方向。
細胞受到UV、gamma-radiation或抗癌藥物造成DNA受損時,會啟動許多因子進行DNA之修補,p53即為重要因子之一。p53可在細胞受外界刺激下快速的受活化,透過轉譯後修飾作用增加其穩定性及活性,p53 N端之磷酸化,可減少受E3 ligase Mdm2之ubiquitination而分解,增加其蛋白之穩定性;p53之C端受乙醯化及磷酸化,則會增加p53與DNA之結合能力,因而增加其轉錄活性。p53下游所調控之基因與細胞週期、DNA修補或凋亡有關,例如活化p21可抑制cdk4造成細胞週期中止,活化Gadd45或CHK1會誘導DNA之修補,增加DR5、Fas、Bax和PUMA等基因表現會使細胞趨向凋亡,以上之作用皆可抑制不正常細胞之增生,因此p53是抑癌基因。臨床上發現之許多癌症,其p53有所突變,因此癌細胞之DNA因抗癌藥造成損傷時,細胞週期無法中止、也無法進行細胞凋亡,因而減低抗癌藥之細胞毒殺作用。 本論文發現,MTX處理A549肺腺癌細胞8小時,即可引發細胞凋亡及細胞週期中止於 S phase,此作用可能是透過活化p53而來;MTX增加p21之蛋白表現,可能透過某種激酶 (kinase) 磷酸化p53之Ser 15和Ser 392,再經由抑制HDAC活性增加p53轉譯後修飾之Lys 373/382乙醯化,因而增加p53之穩定性及活性。我們也發現A549細胞處理MTX四天會促使NF-kappaB之活化,有可能會增加癌細胞之抗藥性。 | zh_TW |
dc.description.abstract | Methotrexate (MTX) is a dihydrofolate reductase inhibitor, and has been used in childhood acute leukemia for almost 60 years. MTX ceases intracellular folate metabolism, blocks purine and thymidylate synthesis and results in cell cycle arrest and apoptosis. Histone deacetylase (HDAC) removes the acetyl group from histone, makes chromatin structure more compact and silences genes. HDACs overexpression has been found in tumors thus inhibits tumor suppressor genes. HDAC inhibitors reactivate these tumor suppressor genes and could serve as potential anticancer drugs.
p53 can be quickly activated upon different kinds of cellular stress and is responsible for the transcriptional activation of a series of proteins involved in cell cycle control, apoptosis, senescence and DNA repair. Post-translational modification of p53 plays a critical role in regulating its activity and stability. Once stabilized and activated, p53 serves as a tumor suppressor and prevents abnormal cell growth. Mutant p53 is frequently observed in many cancers and render them more resistant to genotoxic drugs. We found that, in A549 lung adenocarcinoma cells, MTX arrested cell cycle in S phase and promoted apoptosis after 8-hour treatment. This phenomenon might be caused by p53 activation. MTX induced p53 Ser 15 and Ser 392 phosphorylation, inhibits HDACs activity and promoted its acetylaion on Lys 373/382. NF-kB activation and its downstream gene ICAM-1 exprssion were seen after 4-day exposure to MTX, implying the possible occurrence of MTX resistance. | en |
dc.description.provenance | Made available in DSpace on 2021-06-13T00:04:03Z (GMT). No. of bitstreams: 1 ntu-96-R94443008-1.pdf: 2816149 bytes, checksum: e8da03e2ed8bd6a37e06d99df4e777c3 (MD5) Previous issue date: 2007 | en |
dc.description.tableofcontents | 縮寫表 i
中文摘要 ii Abstract iii 目錄 iv 緒論 1 研究動機 24 實驗材料與方法 25 結果 32 討論 50 結論 53 參考文獻 54 | |
dc.language.iso | zh-TW | |
dc.title | Methotrexate引發細胞週期中止及凋亡之研究 | zh_TW |
dc.title | Investigation of Methotrexate-Induced Cell Cycle Arrest and Apoptosis | en |
dc.type | Thesis | |
dc.date.schoolyear | 95-2 | |
dc.description.degree | 碩士 | |
dc.contributor.oralexamcommittee | 鄭安理(Ann-Lii Cheng),吳明賢 | |
dc.subject.keyword | 細胞週期,抗癌藥,細胞凋亡, | zh_TW |
dc.subject.keyword | p53,Methotrexate,cell cycle,apoptosis,cancer, | en |
dc.relation.page | 66 | |
dc.rights.note | 有償授權 | |
dc.date.accepted | 2007-07-30 | |
dc.contributor.author-college | 醫學院 | zh_TW |
dc.contributor.author-dept | 藥理學研究所 | zh_TW |
顯示於系所單位: | 藥理學科所 |
文件中的檔案:
檔案 | 大小 | 格式 | |
---|---|---|---|
ntu-96-1.pdf 目前未授權公開取用 | 2.75 MB | Adobe PDF |
系統中的文件,除了特別指名其著作權條款之外,均受到著作權保護,並且保留所有的權利。